RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

RELMADA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.16+0.06 (+1.94%)

Close on Oct 19, 2026

Market cap: $355.11M
P/E (TTM): –
Dividend yield: –

RELMADA THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2019 2019-06-30	Q3 2019 2019-03-31	Q2 2019 2018-12-31	Q1 2019 2018-09-30	Q4 2018 2018-06-30	Q3 2018 2018-03-31	Q2 2018 2017-12-31	Q1 2018 2017-09-30	Q4 2017 2017-06-30	Q3 2017 2017-03-31	Q2 2017 2016-12-31	Q1 2017 2016-09-30	Q4 2016 2016-06-30	Q3 2016 2016-03-31	Q2 2016 2015-12-31	Q1 2016 2015-09-30	Q4 2013 2013-12-31	Q3 2013 2013-09-30
Research & Development	8.39	8.09	8.07	4.04	2.82	12	11	11	11	13	15	10	14	16	27	25	25	34	17	14	3.07	1.28	1.26	1.42	0.96	1.67	0.15	0.17	0.18	0.49	0.25	0.36	0.61	0.61	2.12	2.87	-4.27	-0.27
General & Administrative	6.62	11	12	6.29	7.40	6.27	8.08	12	8.10	9.68	12	12	12	12	12	13	8.91	8.66	9.13	8.38	1.07	1.43	2.22	0.99	0.97	0.88	1.31	0.82	1.60	1.79	1.28	1.25	2.49	2.14	3.60	1.76	-0.79	-0.21
Operating Expenses	15	19	20	10	10	18	19	23	19	23	27	23	26	28	39	38	34	43	26	22	4.14	2.70	3.48	2.41	1.93	2.55	1.46	0.98	1.78	2.28	1.54	1.62	3.10	2.75	5.72	4.63	-5.06	-0.48
Operating Income	-15	-19	-20	-10	-10	-18	-19	-23	-19	-23	-27	-23	-26	-28	-39	-38	-34	-43	-26	-22	-4.14	-2.70	-3.48	-2.41	-1.93	-2.55	-1.46	-0.98	-1.78	-2.28	-1.54	-1.62	-3.10	-2.75	-5.72	-4.63	-5.06	-0.48
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.00	0.11	0.07
Interest & Investment Income	2.30	0.96	0.39	0.25	0.32	0.44	0.65	0.86	0.96	1.06	1.26	1.32	1.36	1.21	–	0.00	–	0.00	0.00	0.01	0.01	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	0	-0.67	-0.03	-0.02	-0.12	-0.34	-0.12	-0.05	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	2.10	0.41	0.47	0.24	0.35	0.66	0.42	1.28	1.05	1.16	1.66	0.69	0.72	1.83	0.76	-1.45	-0.20	0.05	-0.09	0.19	0.01	0.02	-3.65	-0.97	-1.42	-0.65	0.03	0.00	0.15	0.30	0.51	-0.02	-0.21	0.89	3.26	9.29	-0.11	-1.08
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-30	-36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-34	-43	-27	-22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-40	-34	-43	-27	-22	-4.12	-2.69	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-40	–	–	–	-22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-13	-19	-20	-10	-9.87	-18	-19	-22	-18	-22	-25	-22	-25	-26	-38	-40	-34	-43	-27	-22	-4.12	-2.69	-7.13	-3.38	-3.35	-3.20	-1.43	-0.98	-1.63	-1.98	-1.03	-1.64	-3.32	-1.86	-2.46	4.66	-5.17	-1.57
EPS (Basic)(per share)	-0.11	-0.22	-0.33	-0.30	-0.30	-0.58	-0.62	-0.72	-0.59	-0.72	-0.84	-0.73	-0.84	-0.87	-1.26	-1.40	-1.80	-2.44	-1.56	-1.34	-0.50	-0.36	-1.12	-1.08	-1.07	-1.04	-0.44	-0.32	-0.54	-0.64	-0.36	-0.56	-1.10	-0.60	-0.88	1.72	-42.00	-12.80
EPS (Diluted)(per share)	-0.11	-0.22	-0.33	-0.30	-0.30	-0.58	-0.62	-0.72	-0.59	-0.72	-0.84	-0.73	-0.84	-0.87	-1.26	-1.40	-1.80	-2.44	-1.56	-1.34	-0.50	-0.36	-1.12	-1.08	-1.07	-1.04	-0.44	-0.32	-0.54	-0.64	-0.36	-0.56	–	-0.60	-0.88	1.44	-42.00	-12.80
Shares Outstanding (Basic, Weighted)(shares)	112	87	61	33	33	30	30	30	30	30	30	30	30	30	30	–	19	17	17	17	8.25	7.51	6.40	3.14	3.14	3.14	3.14	3.13	3.05	3.01	3.01	3.01	3.01	3.00	2.86	2.70	–	0.12
Shares Outstanding (Diluted, Weighted)(shares)	112	87	61	33	33	30	30	30	30	30	30	30	30	30	30	28	19	17	17	17	8.25	7.51	6.40	3.14	3.14	3.14	3.14	3.13	3.05	3.01	3.01	3.01	2.50	3.00	2.86	3.23	–	0.12
Net Interest Income	–	–	–	–	–	–	–	–	–	–	1.26	1.32	1.36	1.21	1.11	0.33	0.16	0.30	0.32	0.42	0.01	0.02	-0.14	-0.65	-0.63	-0.40	-0.31	0.00	–	–	–	0.00	0.00	0.00	–	0.00	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -94.0%

Financial strength

Current ratio: 29.52
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 152.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.72
Dividend yield: –